My translation: A far more patient-friendly therapy for (all) pulmonary mycobacterial infection (which doesn't come with the nasty side effects and non-compliance caused by systemic toxicity) is 'OURS TO OWN'
Before I offer my No.1 reason for the current insider buying, arguably the most important issue to ponder is the timing of the buying. Why buy now rather than in a month or two?
The obvious potential explanation for buying now is that the Company anticipates launching the planned Arikace Expanded Access Program perhaps as early as Q1, and that the insiders are expecting a revenue explosion to trigger a share price explosion.
Another dateline that may be of importance would be the 2nd week of March 2013, when there might be a conference call to discuss the end of the year financials. Would it be possible to have some clarity on Dog Trials and Expanded Access Program by then? Wonder if Lewis or ther directors will purchase any more shares in the near future?
Perhaps they share my expectation that if the preliminary report due around the middle of this year confirms that Arikace delivers, with negligible systemic toxicity, an effective concentration of its amikacin cargo to a pulmonary pseudomonas infection, the FDA will welcome an early opportunity to demonstrate its willingness to be more flexible - by approving Arikace for the treatment of all pulmonary bacterial infections for which amikacin injection is already an FDA-approved therapy.